|

PET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 Expression

RECRUITINGN/ASponsored by Peking University First Hospital
Actively Recruiting
PhaseN/A
SponsorPeking University First Hospital
Started2024-05-28
Est. completion2025-07-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06289517

Summary

This project uses HER2 protein as the target group of radiodrugs to explore the diagnostic efficacy, safety and metabolic characteristics of 68Ga-Her2-affibody in the expression status of HER2, aiming to provide a new imaging method for the determination of HER2 status in breast cancer At the same time, it also provides new methods and means for early diagnosis, accurate staging, recurrence judgment, treatment decision-making and prognosis judgment of malignant tumors such as lung cancer, gastrointestinal cancer and bladder cancer, and provides scientific basis for precise treatment of malignant tumors.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

\- patients with confirmed or suspected cancer; Signed written informed consent

Exclusion Criteria:

\-

Conditions2

CancerNeoplasms

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.